Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430261 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
A Phase 2 study of Lung Cancer and Adenocarcinoma, sponsored by Swedish Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00430261 is a Phase 2 study of Lung Cancer and Adenocarcinoma that has completed, run by Swedish Medical Center. The registered enrollment target is 20 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00430261, a Phase 2 study of Lung Cancer and Adenocarcinoma, has completed, sponsored by Swedish Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.
Conditions Studied
Interventions
- DRUG sunitinib
Study Locations (1)
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430261
The ClinicalTrials.gov registry entry for NCT00430261 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Swedish Medical Center, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which sunitinib is the first listed.
NCT00430261 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00430261 about?
NCT00430261 is a clinical study titled "Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma". This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.
What is the current status of trial NCT00430261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-01. Estimated completion is 2010-10.
What conditions does trial NCT00430261 study?
This clinical trial studies the following conditions: Lung Cancer, Adenocarcinoma.
What interventions are being tested in trial NCT00430261?
The interventions under investigation include: sunitinib (DRUG).
Who is sponsoring clinical trial NCT00430261?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00430261 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.